Can Breast Cancer Survivors Take Hormone Therapy? The Answer Is Changing

Imagine sitting in your oncologist’s office. You’re three years into aromatase inhibitor therapy for stage I hormone receptor–positive breast cancer. You haven’t slept through the night in months. Hot flashes interrupt your days. Brain fog makes it hard to concentrate. Sex is painful. You look at your doctor and ask the question you’ve been building the courage to ask:

“Can’t I start hormone therapy? I am miserable.“

And the answer comes back, almost reflexively: “No. Estrogen feeds your cancer.“

That exchange — drawn directly from a landmark paper just published in the Journal of Clinical Oncology — captures a conversation happening in oncology offices across the country. And according to two of the nation’s leading experts, it’s a conversation that needs to change.

A Landmark Paper Has Entered the Room

In March 2026, Dr. Linda Bosserman (City of Hope) and Dr. Don Dizon (Tufts Medicine) — both Fellows of ASCO — published “Menopausal Hormone Therapy After Breast Cancer: Personalization, Not Prohibition” in the Journal of Clinical Oncology.

Their argument, in plain terms: the blanket prohibition against menopausal hormone therapy (MHT) for breast cancer survivors is not supported by the totality of the evidence — and it is causing real harm to real women.

Dr. Dizon serves as a Learn Look Locate Medical Advisor, guiding our dedicated resource on sexual health and side effects after breast cancer treatment. His voice matters here, and so does this paper.

The FDA Just Changed Something Important

In November 2025, the U.S. Food and Drug Administration made a significant move: it removed the black box warning that had long linked menopausal hormone therapy to breast cancer, cardiovascular disease, and stroke. The FDA’s basis? The totality of the evidence now shows that the benefits of MHT generally outweigh the risks.

ASCO responded by reaffirming its position that systemic MHT remains contraindicated after breast cancer, particularly hormone receptor–positive disease.

Drs. Bosserman and Dizon respectfully but directly push back — and they bring the data with them.

Where the “Estrogen Causes Cancer” Story Came From

The fear of hormone therapy traces back to the Women’s Health Initiative (WHI), a large trial launched in the 1990s. In 2002, an interim analysis suggested more breast cancer cases among women taking a specific combination of hormones — conjugated equine estrogens plus a synthetic progestogen called medroxyprogesterone acetate (MPA). The trial was stopped. The headlines were alarming. A generation of doctors stopped prescribing MHT.

But the paper’s authors walk through critical details that got lost in that moment:

• The increased risk never reached statistical significance in the original analysis.
• The WHI enrolled women with a median age of 63, often more than a decade past menopause, without menopausal symptoms, and with high rates of obesity and smoking. That is not the typical breast cancer survivor asking for help today.
• An extended follow-up over 18 years showed that neither hormone combination was associated with increased all-cause, cardiovascular, or cancer mortality.
• Women taking estrogen alone (without progestogen) actually showed a reduced risk of invasive breast cancer by 23% over 20 years, a finding confirmed in a 2024 meta-analysis of 10 randomized trials.
• Not all hormones are the same. Synthetic progestogens appear to carry a breast cancer risk that bioidentical (micronized) progesterone does not. The E3N cohort study found that synthetic progestogens increased breast cancer risk, while micronized progesterone showed no increased risk at all.

What the Clinical Trials Actually Show for Survivors

Four major trials have evaluated systemic MHT in breast cancer survivors: HABITS, Stockholm, LIBERATE, and a smaller MD Anderson cohort study. The picture is more nuanced than “never”:

• HABITS found increased recurrence — but used predominantly higher-dose synthetic progestogens, had significant methodological limitations, and showed no difference in cancer mortality even at extended follow-up.
• Stockholm — which used far lower progestogen doses — found no statistically significant increase in recurrence, and no increase in mortality.
• LIBERATE used tibolone, a compound with a distinct pharmacological profile that was rejected by the FDA for safety concerns. It is not standard MHT.
• MD Anderson showed recurrence risk was not elevated among women who took estrogen, with numerically fewer breast cancer events compared to those who did not.

A 2024 meta-analysis combining HABITS, Stockholm, and three prospective cohort studies found no statistically significant increased risk of breast cancer or breast cancer mortality with MHT.

What About Local (Vaginal) Hormonal Therapy?

Here, the evidence is even clearer. A 2025 systematic review and meta-analysis of eight trials covering more than 50,000 women-years — including women on aromatase inhibitors — found no significant increase in breast cancer recurrence or mortality with low-dose vaginal estradiol.

And for vaginal testosterone specifically: four randomized trials in women with hormone receptor–positive breast cancer on aromatase inhibitors showed improvement in vulvovaginal atrophy and low sexual desire without raising systemic estradiol levels.

Beyond Breast Cancer: What MHT Might Actually Protect

The authors remind oncologists that treating the whole person means accounting for what untreated menopause does to the rest of the body. Evidence supports MHT’s role in:

• Bone health — reduced fracture risk
• Cardiovascular health — when initiated early after menopause, one study showed a 52% reduction in the composite endpoint of death, heart failure, or heart attack
• Cognitive outcomes — observational and mechanistic data suggest timing and formulation matter

These aren’t minor footnotes. For a 52-year-old woman who may live another 40 years, the downstream risks of untreated menopausal symptoms deserve honest consideration alongside cancer risk.

The Call to Action: Conversation, Not Contraindication

Bosserman and Dizon are not advocating for putting every breast cancer survivor on hormone therapy. They are advocating for something more fundamental: an honest, individualized conversation.

They call on oncologists and professional societies — ASCO, ACOG, and others — to re-evaluate the literature and create space for nuanced, patient-centered decision-making. They call for new research that specifies formulation, dose, and route; reflects contemporary breast cancer treatment; and gives women real data to weigh.

Their conclusion: “Women with breast cancer should be treated as partners in their own care. They deserve an accounting of what is known, what is uncertain, what is feared, what evidence we have, and what options and trials exist.”

What This Means for You

If you are a breast cancer survivor struggling with:

• Hot flashes, night sweats, or insomnia
• Brain fog or difficulty concentrating
• Vaginal dryness, pain during intimacy, or recurrent urinary infections
• Low libido or mood changes

You deserve more than a reflexive “no.” You deserve a conversation.

Bring this topic to your next appointment, especially if you’ve completed or never had to start antiestrogen therapy. Ask your oncologist specifically about your hormone receptor status, your cancer stage, your recurrence risk, and which formulations might or might not apply to you. For most, vaginal hormonal therapy is not contraindicated because it carries a different evidence profile than systemic therapy, and it may be appropriate for your symptoms.

And if your provider isn’t familiar with the most current evidence, it is entirely appropriate to say: “I’ve been reading about the recent JCO paper on personalized MHT after breast cancer. Can we talk through what it means for me?”

Learn More with Dr. Dizon

Dr. Don Dizon guides our dedicated resource on sexual side effects after breast cancer treatment here at Learn Look Locate. His clinical focus — and his co-authorship of this JCO paper — reflect a commitment to the idea that survivorship care must address the whole person, not just the tumor.

You are not asking for too much. You are asking for the care you deserve.

Frequently Asked Questions

Q1. Can breast cancer survivors take menopausal hormone therapy?
A:It depends on your individual situation — and that conversation is more open than it used to be. If you are taking an anti-estrogen for breast cancer, then no, menopausal hormone therapy should not be used. If you weren’t a candidate for it, or if you’ve completed a course of treatment, that’s a different story. For decades, it was considered off-limits for breast cancer survivors, particularly those with hormone receptor–positive disease. But a growing body of evidence, including a 2026 paper in the Journal of Clinical Oncology, shows the data are far more nuanced. The right answer for you depends on your cancer stage, receptor status, recurrence risk, and the severity of your symptoms. Ask your oncologist for a personalized discussion — not a blanket no

Q2. What is the difference between systemic and local (vaginal) hormone therapy?
A: Systemic hormone therapy — pills, patches, or injections — impacts the entire body by raising hormone levels in the blood. Local vaginal hormone therapy — low-dose creams, suppositories, tablets, or rings — acts primarily in the vaginal tissue with minimal absorption into the bloodstream. The evidence profile for local vaginal therapy is considerably more reassuring. A 2025 meta-analysis of more than 50,000 women-years showed no significant increase in breast cancer recurrence or mortality with low-dose vaginal estradiol, even in women on aromatase inhibitors.

Q3. I’m on an aromatase inhibitor. Are my symptoms considered normal?
A: Yes, and they are often more severe than natural menopause. Hot flashes, joint pain, vaginal dryness, brain fog, insomnia, and low libido are all common side effects of aromatase inhibitor therapy. They are also medically significant — severe enough that many women stop treatment early, which can compromise their cancer outcomes. You are not overreacting. These symptoms deserve real attention and real solutions. While on an aromatase inhibitor, menopausal hormone therapy is contraindicated.

Q4. Are all hormone therapies the same?
A:No — and this distinction matters enormously. Synthetic progestogens (like medroxyprogesterone acetate) appear to carry different risks than bioidentical micronized progesterone. Conjugated equine estrogens behave differently from oral 17-beta estradiol. Research consistently shows that formulation, dose, and route of administration significantly affect outcomes. The old blanket warnings did not make these distinctions. Your provider should.

Q5. What is vaginal testosterone, and is it safe for breast cancer survivors?
A: Vaginal testosterone is applied locally to address vaginal dryness, pain, and low sexual desire — common side effects of aromatase inhibitor therapy. Four randomized clinical trials in hormone receptor–positive breast cancer survivors showed it improved symptoms without raising systemic estradiol levels. Long-term observational data on testosterone implants also showed no increase in breast cancer incidence over 10 to 15 years. It is not standard of care, and unfortunately, there are no testosterone formulations for women in the United States. But, it is still something you can discuss with your oncologist or primary care doctor (e.g., internist or gynecologist).

Q6. What did the FDA change in 2025?
A: In November 2025, the FDA removed the black box warning that had long linked menopausal hormone therapy to breast cancer, cardiovascular disease, and stroke. This was based on a comprehensive review of evidence indicating that, for most women, the benefits of MHT outweigh the risks. ASCO has maintained its position that systemic MHT remains contraindicated after hormone receptor–positive breast cancer, but leading oncologists, including Dr. Don Dizon, are calling for a more individualized, evidence-based approach.

Q7. What should I say to my doctor?
A: Start the conversation directly: “I’m struggling with menopausal symptoms, and I want to talk through my options, including whether any hormonal therapies are appropriate for my situation.” If your provider is not familiar with the latest evidence, it is entirely reasonable to cite the 2026 JCO paper by Bosserman and Dizon and request a referral to a menopause specialist or gynecologic oncologist specializing in survivorship care.

Q8. Where can I learn more about sexual health after breast cancer?
A: Dr. Dizon guides our dedicated resource on sexual side effects after breast cancer treatment at Learn Look Locate — covering vaginal dryness, pain during intimacy, low libido, and the full range of treatment options available to survivors.

Reference: Bosserman LD, Dizon DS. Menopausal Hormone Therapy After Breast Cancer: Personalization, Not Prohibition. J Clin Oncol. Published March 31, 2026. DOI: 10.1200/JCO-25-03121

This article is for educational purposes and does not constitute medical advice. Always discuss treatment decisions with your oncology care team.